Join AIM-LO - an EHR-based medical practice assessment (MPA) initiative in dyslipidemia management.
Benefits of participating in AIM-LO:
Examine your own practice patterns around management of dyslipidemia in your patients with ASCVD
Assess your adherence to the 2021 CCS Dyslipidemia Guidelines for treatment intensification in patients at high risk of events whose LDL-C ≥1.8mmol/L and triglycerides ≥1.5 mmol/L
Effectively engage your patients in discussions around their treatment options for the management of their dyslipidemia
This quality improvement initiative has been reviewed and approved by an independent ethics review board.

AIM-LO (ASCVD Identification and Management of Lipid Lowering Therapy) is a medical practice assessment (MPA) initiative available to Canadian specialists including cardiologists and endocrinologists.

This MPA leverages data available in the Electronic Health Records (EHR) of participating physicians to identify patients at high risk of CV events who are not receiving guidelines-directed medical therapy for their dyslipidemia (based on the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines).

To execute this program, The CPD Network has partnered with EOCI and Ensho Health to analyze the EHRs of participating physicians.

Criteria for identification of high-risk patients have been defined by our Scientific Committee composed of lipid experts and guidelines authors.


Scientific Committee

(Click picture for bio)


The committee is responsible for the development, scientific integrity, and implementation of the program and includes:




About AIM-LO

AIM-LO has been designed to address the gaps between knowledge and practice when it comes to dyslipidemia management. While most cardiologists know and understand the recommendations from the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines, it is challenging to apply these into clinical practice for a variety of reasons.

Evidence generated over the past decade has established that significantly reducing LDL-C levels leads to plaque regression and lowers the risk of cardiovascular events. Intensively managing dyslipidemia improves outcomes, extends survival, and reduces hospitalizations.

The opportunity for quality improvement (QI) of the care of high-risk patients is considerable and is the focus of this MPA. Sign up to identify patients with dyslipidemia who require treatment optimization as per the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines!

Analyses & Reports

Participant data is analyzed by Ensho Health. The Operations Team of Ensho analyzes the EHRs of participants with optical character recognition, natural language processing and other methods to identify and characterize the lipid lowering treatments of patients with atherosclerotic cardiovascular disease (ASCVD).

See criteria used for patient identification in the FAQ section

Participants are provided with a report after each analysis identifying patients eligible for initiation or intensification of lipid lowering therapy according to the 2021 Canadian Cardiovascular Society Dyslipidemia Guidelines. Reports are available to clinic administrators in the Ensho Health web application and sent directly to physicians via fax, as well as email (if requested). Each participant is also provided with their rate of guideline adherence in the previous three months. Check out the FAQ section for further details.

Data Collection

Ensho processes information using their Apollo automated electronic data capture (aEDC) system.

Optical Character Recognition

Apollo reads and extracts data from all document types including encounter notes, PDF documents, image files and hand-written notes. Each record is converted to machine readable data before it is analyzed so relevant information is never missed.

Natural Language Processing

Specialty-specific extractors analyze data from problem lists, encounter notes, discharge summaries and other unstructured document types (including your short-form).

The data necessary to calculate the primary endpoint will be extracted by Ensho Health. De-identified summary statistics will be provided to the Scientific Committee only.

See also: Privacy and Compliance

Financial Disclosure
Novartis Canada is providing financial support to the CPD-Network for this initiative, but neither the program sponsor, the scientific committee, the program organizer, or anyone else will have access to your individual patient-level data. By electing to participate in AIM-LO, you agree that an aggregate and anonymized report summarizing the findings can be shared with the scientific committee and EOCI.